MBX to advance hypoparathyroidism drug to Phase III trial
The study drug also showed positive results in the six-month open-label extension (OLE) trial (NCT06531941).
23 September 2025
23 September 2025
The study drug also showed positive results in the six-month open-label extension (OLE) trial (NCT06531941).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.